Zobrazeno 1 - 10
of 327
pro vyhledávání: ''
Publikováno v:
Value in Health. 24:1520-1530
Objectives Although there is a growing body of evidence suggesting that cannabinoids may relieve symptoms of some illnesses, they are relatively high-cost therapies compared with illicit growth and supply. This article aimed to comprehensively review
Autor:
Michael N Dalili, José A López-López, Deborah M Caldwell, Kyla H Thomas, Mark Stevenson, David Phillippo, Edna Keeney, Nicky J Welton, Marcus R. Munafò
Publikováno v:
Keeney, E, Welton, N J, Stevenson, M, Dalili, M N, López-López, J A, Caldwell, D M, Phillippo, D M, Munafò, M R & Thomas, K H 2021, ' Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events ', Value in Health, vol. 24, no. 6, pp. 780-788 . https://doi.org/10.1016/j.jval.2020.12.012
Value in Health
Value in Health
OBJECTIVES: Smoking is a leading cause of death worldwide. Cessation aids include varenicline, bupropion, nicotine replacement therapy (NRT), and e-cigarettes at various doses (low, standard and high) and used alone or in combination with each other.
Publikováno v:
Value in Health
Objectives We applied principles for conducting economic evaluations of factorial trials to a trial-based economic evaluation of a cluster-randomized 2 × 2 × 2 factorial trial. We assessed the cost-effectiveness of atorvastatin, omega-3 fish oil, a
Autor:
Edith A. Perez, Hans-Peter Goertz, Joseph B. Babigumira, Louis P. Garrison, Solomon J. Lubinga, C. Tournier
Publikováno v:
Value in Health. 22:408-415
Objective The APHINITY trial assessed the effectiveness and the safety of adding pertuzumab to trastuzumab and chemotherapy (THP) compared to trastuzumab and chemotherapy (TH) in the adjuvant management of human epidermal growth factor 2-positive (HE
Autor:
Nancy Risebrough, Claus Vogelmeier, S. Shukla, Chris Compton, Isabelle Boucot, Aurelio Martín, Edward Kerwin, Afisi S. Ismaila, François Maltais, Paul W. Jones, Dhvani Shah, R. Kendall, L. Tombs, Leif Bjermer, David A. Lipson
Publikováno v:
Value in Health. 24:S214
Publikováno v:
Value in Health. 20:705-709
Background Economic evaluations often measure an intervention effect with mean overall survival (OS). Emerging types of cancer treatments offer the possibility of being "cured" in that patients can become long-term survivors whose risk of death is th
Publikováno v:
Value in Health, 20(3), 388-396. ELSEVIER SCIENCE INC
Background: In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction. Objectives: To determine the incremental cost-effectiveness
Publikováno v:
Value in Health. 23:S266-S267
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial
Autor:
Andrew C. Embleton, Sebastian Hinde, Timothy J. Perren, David Epstein, Adrian Cook, Mark Sculpher
Publikováno v:
Value in Health. 19:431-439
Background Bevacizumab is used extensively in the treatment of cancer, including advanced ovarian cancer, for which results of the International Collaborative Ovarian Neoplasm (ICON) 7 trial have been recently reported. The National Institute for Hea
Publikováno v:
Value in Health. 23:S37